PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27231113-3	2017	We describe an interaction between the new anticancer agent idelalisib (CYP 3A4 inhibitor) and diazepam (CYP 3A4 substrate) that resulted in altered mental status and type II respiratory failure resulting in hospitalization.	idelalisib	60-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	72-79	
29572333-8	2018	Only idelalisib showed strong inhibition of CYP3A, and lumacaftor behaved as a strong CYP3A inducer.	idelalisib	5-15	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	44-49	
27231113-3	2017	We describe an interaction between the new anticancer agent idelalisib (CYP 3A4 inhibitor) and diazepam (CYP 3A4 substrate) that resulted in altered mental status and type II respiratory failure resulting in hospitalization.	idelalisib	60-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	105-112	
26242379-5	2016	Idelalisib is metabolized primarily via aldehyde oxidase (AO) and, to a lesser extent, via cytochrome P450 (CYP) 3A.	idelalisib	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	91-115	
25760671-1	2015	Idelalisib, a potent phosphatidylinositol-3-kinase delta (PI3Kdelta) inhibitor, is metabolized primarily by aldehyde oxidase to form GS-563117 and to a lesser extent by cytochrome P450 (CYP) 3A and uridine 5"-diphospho-glucuronosyltransferase 1A4.	idelalisib	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	169-193	
25760671-2	2015	In vitro, idelalisib inhibits P-glycoprotein (P-gp) and organic anion transporting polypeptides 1B1 and 1B3, and GS-563117 is a time-dependent CYP3A inhibitor.	idelalisib	10-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	143-148	
25760671-8	2015	Coadministration with idelalisib increased plasma exposures of midazolam (138% and 437% for maximum observed plasma concentration [Cmax ] and area under the plasma concentration-time curve from time 0 extrapolated to infinity [AUCinf ], respectively), consistent with the in vitro finding of CYP3A inhibition by GS-563117.	idelalisib	22-32	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	292-297	
25760671-9	2015	Rifampin caused a substantial decrease in idelalisib (58% and 75%, Cmax and AUCinf , respectively) and GS-563117 exposures, indicating an enhanced contribution of CYP3A to idelalisib metabolism under a strongly induced state.	idelalisib	172-182	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	163-168